Introduction
The cytochromes P-450 (P-450s) are a 'superfamily' of haem 6-containing oxidase proteins [ 1,2], which catalyse an array of oxidative reactions with a plethora of organic substrates. P-450 enzymes are found throughout Nature, from organisms as simple as bacteria (and archaeons [3] ) to higher eukaryotes. The 1'-450s have enormous biotechnological potential because they catalyse the controlled activation of 02, with the potential for stereospecific and regiospecific insertion of oxygen atoms into organic molecules. This potential has already been realized with the use of the P-450s in the commercial manufacture of steroids [4] , and the process is continually being developed and improved [ 51.
Mammals have numerous forms of membrane-bound P-450 that catalyse various forms of reaction (e.g. hydroxylation, epoxidation, Noxidation and reductive dehalogenation) [6] and are vital to a number of physiological processes, including steroid syntheses and interconversions, the manufacture of eicosanoid derivatives for cellular signalling, and xenobiotic detoxification. The importance of mammalian hepatic P-450s in the metabolism of drugs is a subject of great importance to the pharmaceutical industry. The P-450s, the so-called 'phase I' enzymes, represent a 'first line of defence' when the body is exposed to xenobiotics, and the multiple hepatic forms of P-450 catalyse oxidative reactions on thousands of drugs and other foreign chemicals to which the body is exposed. Examples are the oxidations of ethanol, aspirin, chloroform and polycyclic aromatic hydrocarbons. These oxidations are often designed to increase the watersolubility of xenobiotics to facilitate their excretion directly, or to provide functional groups for recognition by 'phase 11' drug-metabolizing enzymes, such as glutathione S-transferases or UDP-glucuronyl transferases. However, factors
Abbreviations used: hq, hydroquinone; ox, oxidized; sq, semiquinone. ' T o whom correspondence should be addressed. such as industrial pollution and the massive development of the pharmaceutical industry in the past century has meant that we have been exposed to a vast number of new chemicals that can act as substrates for the P-450s (many forms of mammalian P-450 are rather non-specific). It is now well recognized that the P-450s are capable of converting a number of compounds into more dangerous, even genotoxic, derivatives. Examples are the epoxidations of benzo [ulpyrene (P-450 1Al) and aflatoxin B1 (1'-450 3A4) [7] . It is ironic that an enzyme system that evolved to defend the body against harmful organic compounds can also be tricked into acting against it, due to the rate of human evolution of new chemicals outstripping the genetic evolution of the P-450s.
Although there is intense medical and pharmaceutical interest in the mammalian P-450s, the expression and study of the structural properties of these enzymes is hampered by the fact that they are integral membrane proteins (as are their redox partners). However, the bacterial P-450s are soluble; this has simplified the overexpression and purification of these forms [8] . In many respects, the entire P-450 field has been led forward by the advances made through kinetic, spectroscopic and structural analysis of a small number of bacterial forms. There are currently six atomic structures available for bacterial P-450s [9-141. For the two most important of these enzymes (P-450cam and P-450 BM3), the structures of both substratebound and free forms have been determined [9, 10, 15, 16] . T h e camphor hydroxylase P-450cam from Pseudoinonus putida has been one of the most intensely studied of all enzymes over the last quarter of a century [17] ; the analysis of this enzyme has provided us with most of our knowledge on the structure and mechanism of P-450. However, in the past 5-10 years there has been enormous interest in the characterization of the fatty acid hydroxylase P-450 BM3 from Bacillus rneguteriurn [18] . This shift in emphasis results from the realization that P-450 BM3 uses a simi-lar reductase system to that of most eukaryotic P-450s, and to its homology with the nitric oxide synthases [8, 19] .
Flavocytochrome P-450 BM3: an important model enzyme
The P-450s can be divided conveniently into two major classes, based on the type of redox systems used. In class I (or B-class), the P-450 is the terminal component of a three-protein electron transport chain, receiving electrons one at a time from either a small FMN-containing flavodoxin or an iron-sulphur ferredoxin. Typical of this class are eukaryotic mitochondria1 forms and the vast majority of bacterial P-450s (e.g. P-450cam). In class I1 (or E-class) P-450s, the P-450 is reduced by a single NADPH-dependent FADand FMN-containing P-450 reductase. The hepatic drug-metabolizing P-450s are good representatives of the class I1 system ( [8] ; see also Kirill Degtyarenko's web site, www.icgeb-.trieste.it/p450/). P-450 BM3 (CUP 102A1) is a special example of the class I1 system (see accompanying article in this colloquium by Chapman et al.) and has many intriguing properties. P-450 BM3 has the highest mono-oxygenase activity reported for any P-450 (more than 4500 min-' with palmitate and pentadecanoate) and catalyses the NADPH-dependent hydroxylation (usually at the 0-1 to 0-3 positions) of a wide range of saturated and unsaturated fatty acids, alcohols and amides (from approx. CI2 to C,,) [8] . Expression of the gene (cypZO2Al) is inducible by barbiturates and certain fatty acids and is controlled at the transcriptional level by both positive and negative regulatory DNA-binding proteins [21] . P-450 is soluble and uses a similar redox partner to that of the mammalian drug-metabolizing forms (a diflavin P-450 reductase). This reductase (C-terminal) is also fused to the P-450 (N-terminal) via a short peptide linker; a similar arrangement as seen in the nitric oxide synthases [19] . The gene has been cloned and overexpressed in Escherichia coli, and the flavocytochrome has been purified to homogeneity [22] .
More recently, the PCR-generated subgenes encoding the isolated P-450 (haem) and reductase (diflavin) domains were also overexpressed and the proteins purified, as were the ferredoxin reductase-like and flavodoxin-like subdomains of the diflavin domain [18, 23] . The atomic structures of the substrate-free and substrate (palmitoleate)-bound forms of the haem domain of P-450 BM3 have been determined [10, 16] . These structures have revealed targets for rational sitedirected mutagenesis aimed at the determination of the roles of active-site amino acids. Such studies have identified determinants of haem binding and haem iron spin-state control (Trp-96 [24] ), of regiospecificity of substrate oxidation (Phe-87 [25] ) and of fatty acid ligation at the active site (Arg-47 [26] ) (Figure 1 ). Our recent studies have shown that there is conformational communication between the haem and diflavin domains of P-450 BM3. Binding of NADP' to its site on the diflavin domain induces a structural change in the haem domain that results in a marked increase in affinity for substrate-like inhibitor compounds [27] .
Redox chemistry of the P-450s
In P-450 BM3 and other P-450s, mono-oxygenation of substrate is achieved by two successive one-electron transfers to the haem from the redox partner (Scheme 1). The first transfer (reducing Fe3+ resting haem to the Fez+ state) occurs after substrate binds at the P-450 active site. After reduction, O2 binds to the Fez+ haem to form 'oxy-P-450'. Further reduction by a second electron from the redox partner allows the completion of the P-450 catalytic cycle, although intermediates after the second electron transfer to oxy-P-450 remain to be identified. These intermediates are so short-lived that they have been impossible to isolate spectroscopically. However, a likely model involves the second reduction leading to the formation of a ferric peroxy species. Two protons, probably from solvent water, are then delivered to the active site and one atom of oxygen is lost to form water. This leaves a high-valency iron-oxo species, possibly FeS+=O, which can be stabilized by a number of resonance structures involving the haem ring and the oxygen. This compound then abstracts a hydrogen atom from bound substrate to form a substrate radical and this, in turn, collapses via an oxygen rebound mechanism to generate ferric P-450 and oxidized product [ 171.
The product then dissociates to regenerate the resting P-450 form (Scheme 1).
T h e catalytic cycle of various P-450s can be driven artificially and by non-physiological protein redox partners. Oxygen-donor molecules such as Hz02 and alkyl hydroperoxides can provide both the oxygen and electrons required for P-450 function [28] . It has also proved possible
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to drive P-450 BM3-catalysed and mammalian P-450-catalysed oxidations with reasonably good efficiency via an electrode [29] . In the past few years, breakthroughs have been made in the expression of mammalian P-450s in E. c-oli. This has led to the discovery that the E. coli NADPHflavodoxin reductase and flavodoxin electron transport system can support the activity of heterologously expressed P-450s [30] . Th' is occurs through a Ping Pong mechanism in which the flavodoxin acts as a single-electron shuttle between the flavodoxin reductase and the 1'-450
The ability to overexpress and purify the component domains and subdomains as well as the intact flavocytochrome has simplified the study of the redox properties of P-450 BM3. We have analysed these properties by using techniques such as stopped-flow absorbance spectrophotometry, EPR and redox potentiometry to 1311.
understand the electron transfer processes and their mechanisms of regulation.
Electron transfer and its control in flavocytochrome P-450 BM3
How does the electron transfer pathway through 1'-450 BM3 operate and how is electron transfer to the haem iron regulated to avoid oxygen reduction (and hence toxic radical production) in the absence of substrate? We have examined this problem by using stopped-flow kinetics to examine individual steps in the catalytic process, and potentiometric titrations to determine the reduction potentials of the flavin and haem cofactors (Figure 2 ). T h e availability of the isolated domains (particularly the flavin-containing domains) proved vital to deconvolute the complex spectral changes observed during anaerobic reductive and oxidative titrations of intact flavocytochrome P-450 BM3, changes that (at certain propionate and is important in maintaining haem iron in the low-spin state [24] . Just above the haem plane is the side-chain of Phe-87.
which interacts with the cu-terminus of fatty acid substrates and prevents cu-oxidation [25] . . .
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Enzyme-Catalysed Electron/Radical Transfer Scheme I Schematic representation of the catalytic cycle of flavocytochrome P-450 BM3
Electrons are represented as filled circles. Two electrons are derived ultimately from NAD(P)H and are transferred (as a hydride) t o the FAD (dehydrogenation). Electrons are passed to the FMN. which acts as a shuttle, passing electrons one at a time to the haem iron (electron transfer). Electrons cannot pass from FMN to haem until fatty acid substrate (SH) is bound, owing to SH-induced elevation of the reduction potential of the P-450 BM3 haem iron. Thereafter, one electron is transferred to form ferrous haem, which binds 0;. A second electron is passed t o this higher potential oxy-P-450 species; hydroxylation of substrate follows (mono-oxygenation). Dissociation of product (oxygenated substrate [ [33] . The rate of electron transfer between flavins (measured by the formation of a blue flavin semiquinone at 600 nm) is very fast: 452 s-' at 25°C compared with the rate of fatty acid hydroxylation (only approx. 77 s-' at 30°C for pentadecanoate [34] ). Thus electron transfers through the flavins of P-450 BM3 seem unlikely to limit fatty acid oxidation to any significant extent. Indeed, it has been reported that the reduction of ferricytochrome c-(via the FMN of I-'-450 BM3) can occur simultaneously with the hydroxylation of myristic acid, without affecting the rate of either process [35] . In the absence of fatty acid, NADPH converts 1'-450 BM3 to a three-electron reduced state. The FAD sqlhq couple is approx. 5OmV more negative than the midpoint potential of NADP+/H and the FAD remains as a neutral blue semiquinone [33] . This is confirmed by EPR measurements of NADPH-reduced 1'-450 BM3 [ 321. However, during the oxidation of tetradecanol (a 'slow' substrate; k,,, z 730 min-') two flavin semiquinones are detected (one neutral, one anionic) by EPR. This suggests that, during steady-state fatty acid oxidation, the diflavin domain of 1'-450 BM3 (which can hold up to four electrons) cycles between reduction states 0, 2, 1 and 0 and that the binding of NADP' results in the stabilization of the two-semiquinone state [36] . This might be achieved through the modulation (i.e. increase) of the oxlsq and sqlhq reduction potentials of the FAD of P-450 BM3 by the binding of oxidized nucleotide. We have recently observed such a phenomenon induced by the binding of adenosine Z'-monophosphate to the E. c-oli FLDR enzyme [31] . In the absence of fatty acid substrate, the three-electron-reduced state of the flavins accumulates and this leads to a time-dependent reversible inactivation of the activity of P-450 BM3, probably through a slow conformational change [34, 37] . It is tempting to speculate that this is a regulatory mechanism by which the enzyme can 'switch off' and avoid wasteful NADPH oxidation if fatty acid substrate is in short supply [38] .
Reduction of the P-450 BM3 haem iron cannot occur until fatty acid is bound at the active site. Binding of fatty acid induces a lowspin to high-spin shift in the P-4.50 haem iron and results in a change in the visible absorbance maximum (the Soret band) from 419 to 390nm. Binding and spin-shift are extremely fast (more than 800s-' at 25OC). The best substrates [e.g. arachidonate or palmitate (Figure 2) ] convert most (more than 80%) of the resting low-spin P-450 haem iron ( S = 1/2) to the high-spin form (S = 5/2). T h e spin-state conversion is achieved by substrate-dependent dehydration of the active site, specifically the displacement of the sixth ligand to the haem iron (a water molecule). Accompanying the spin-state shift is an elevation of the reduction potential of the haem iron of up to 130 mV (Figure 2 ) [33] . An increase of similar magnitude has been observed for the binding of camphor to P-450cam [39] . It seems that the spin-state of P-450 BM3 is poised deliberately close to the equilibrium between the low-spin and high-spin forms, such that removal of the sixth water ligand by substrate shifts the equilibrium strongly in favour of the high-spin form and acts as a redox 'switch' that opens the gate for electron transfer to the haem iron when substrate is bound [17, 33] . This elegant mechanism avoids the production of harmful superoxide/ H202 in the absence of fatty acids. As shown in Figure 2 , the reduction potential of 1' -4.50 BM3 haem iron increases to such an extent that the equilibration of electrons from FMN becomes feasible. The rate of the first electron transfer to the fatty acid-bound haem is dependent on the nature of the substrate. For instance, rates of 223 s-' (with myristate) and 130 s-' (with laurate) were measured at 25°C by stopped-flow kinetics, after the formation of the CO-adduct of ferrous 1'-450 BM3 at 450 nm [32] . During catalysis, the ferrous iron binds OL rapidly (Scheme 1) and this species is further reduced by a second electron transfer from FMN. It is likely that the reduction potential of the ferrous 'oxy-P-450' is considerably more positive than that of the ferric substrate-bound form, and that the second electron transfer occurs almost simultaneously [ 32,331. Subsequent steps leading to product formation and the regeneration of ferric P-450 BM3 occur too fast to be measured by stopped-flow techniques. P-450 BM3 is a very well evolved enzyme and it is difficult to pinpoint a single rate-limiting step for the wild-type protein. However, the fact that the first FMN-to-haem electron transfer becomes rate-limiting in a number of active-site mutants suggests that this is the key step (M. A. Noble, C. S. Miles, S. K. Chapman, G. A. Reid, R. P. Hanzlik and A. W. Munro, unpublished work).
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Future prospects in the study of flavocytochrome P-450 BM3
The study of P-450 BM3 over the past decade has provided many significant insights into the I 1100
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Enzyme-Catalysed Electron/Radical Transfer structure and mechanism of its mammalian homologues. As with all important enzymes, many of these findings have led to new topics for investigation. Among the most pertinent current problems are the understanding of the conformational properties of the enzyme that underlie such phenomena as the time-dependent inactivation by NADPH [34, 37] and the haem reductiondependent movement of substrate at the active site [40] . However, perhaps the most important question regards the route of electron transfer from the FMN to the haem iron of P-450 BM3. We have investigated this problem by using sitedirected mutagenesis [24] , and examination of the crystal structure of the haem domain indicates that a convenient site for electron transfer from the reductase might exist at the region where the cysteinyl ligand to the iron (Cys-400) is exposed to solvent. Further insight might be obtained from the forthcoming atomic structure of the FMN-haem domain of P-4.50 BM3 [23] .
However, the real answer might come only with the solution of the structure of the intact (119 kDa) flavocytochrome, a task that has until now defeated some of the world's top crystallographers. We wait and hope.
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Introduction
Trimethylamine dehydrogenase (TMADH) is an iron-sulphur flavoprotein from the bacterium i\ldiylopliilus ttietliylott-ophics. TMADH catalyses the oxidative dernethylation of trimethylamine to dimethylamine and formaldehyde [ 11: (CH3)3N + H20+(CH3)2NH + C H 2 0 +2H' +2ep
The crystal structure [2] reveals that the enzyme is a homodimer, and each subunit contains an unusual covalently linked 6-S-cysteinyl FMN cofactor [3-51, a bacterial ferredoxin-type 4Fe-4S centre [6] and ADP [7] . T h e physiological electron acceptor of TMADH is an eleci\bbreviations used: E l l 2 , electron-transferring favoprotein; 'I'MADH, trimethylamine dehydrogenase. "1.0 whom correspondence should be addressed.
tron-transferring flavoprotein (ETF) [8] , a heterodimer containing one equivalent of FAD [8] and AMP [9] , that cycles between the quinone and anionic semiquinone states. T h e reaction catalysed by TMADH can be divided into reductive and oxidative half-reactions (Figure 1) [ 10-141. The reductive half-reaction is resolved into three sequential kinetic phases [ 151 ([ 151;
M.-H. Jang, J. Basran, N. S. Scrutton and R.
Hille, unpublished work): an initial fast phase that represents the reduction of the 6-S-cysteinyl FMN by substrate, an intermediate phase that represents the electron transfer from the reduced 6-S-cysteinyl FMN to generate flavin semiquinone and a reduced iron-sulphur centre, and a slow phase that involves the formation of an unusual spin-interacting state of the enzyme caused by the strong ferromagnetic coupling of the unpaired magnetic moments of the reduced Figure I Reaction sequence of TMADH Abbreviations: F. flaviri; FeS, 4Fe-4S centre; ox, oxidized: red, reduced. Reaction I , two-electron reduction of flavin by amine substrate; reaction 2, one-electi-on transfer t o 4Fe-4S centre; reaction 3, eT complex formation and one-electron transfer to ETF; reaction 4, internal one-electron iransfer to 4Fe-45 centre reaction; 5, eT complex formation and one-electron transfer t o ETF. 
